An inappropriate structure for a decision analytic model can potentially invalidate estimates of cost-effectiveness and estimates of the value of further research. However, there are often a number of alternative and credible structural assumptions which can be made. Although it is common...

The aim of this 6-month project was to undertake a scoping study to provide recommendations for identifying NICE’s methodological research priorities and to establish an initial set of such priorities. Specifically the project had three main objectives: (i) To describe current processes by...

The general issue of balancing the value of evidence about the performance of a technology and the value of access to a technology can be seen as central to a number of policy questions. Establishing the key principles of what assessments are needed, as well as how they should be made, will...

The use of decision-analytic modelling for the purpose of health technology assessment (HTA) has increased dramatically in recent years. Several guidelines for best practice have emerged in the literature; however, there is no agreed standard for what constitutes a `good model' or how models...

<Emphasis Type="Bold">Background: Gastro-oesophageal reflux disease (GORD) causes some of the most frequently seen symptoms in both primary and secondary care. An estimated 4–5 patients (age range 18–60 years) per 10 000 (0.045% of the general population) are receiving maintenance proton pump inhibitors (PPIs)...</emphasis>

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have...

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have...

Background: Gastro-oesophageal reflux disease (GORD) causes some of the most frequently seen symptoms in both primary and secondary care. An estimated 4-5 patients (age range 18-60 years) per 10_000 (0.045% of the general population) are receiving maintenance proton pump inhibitors (PPIs) for...